Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis

NCT01877694 is registered in ClinicalTrials.gov with NovaBay Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01877694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01877694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2013
Completion date
January 31, 2015
Enrollment
217 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial conjunctivitis